Compare MTCH & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTCH | TGTX |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.5B |
| IPO Year | 2004 | 2008 |
| Metric | MTCH | TGTX |
|---|---|---|
| Price | $37.97 | $52.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $35.17 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 3.6M | 2.5M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | 17.82 | ★ 1746.67 |
| EPS | ★ 0.68 | 0.12 |
| Revenue | ★ $3,487,197,000.00 | $2,785,000.00 |
| Revenue This Year | $2.15 | $49.08 |
| Revenue Next Year | $3.82 | $26.69 |
| P/E Ratio | ★ $55.93 | $439.00 |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $28.81 | $25.37 |
| 52 Week High | $41.03 | $59.30 |
| Indicator | MTCH | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 50.66 |
| Support Level | $37.56 | $51.15 |
| Resistance Level | $39.36 | $58.34 |
| Average True Range (ATR) | 1.16 | 2.38 |
| MACD | -0.10 | -0.89 |
| Stochastic Oscillator | 23.66 | 23.07 |
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. It generates the majority of its revenue from the Tinder segment.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.